New 3D scanner could revolutionize how doctors measure kaposi sarcoma
NCT ID NCT06898203
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This study will test a new 3D imaging device called SkinScan3D to see if it can measure Kaposi Sarcoma skin lesions more accurately and consistently than the current manual method. Researchers will compare the two methods in 300 adults with confirmed Kaposi Sarcoma who are starting or already on treatment. The goal is to see if the device is practical and easy to use in everyday clinic settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Nov 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria - Aim 2 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * At least 3 skin lesions * Capable of informed consent * On treatment for Kaposi Sarcoma Exclusion Criteria - Aim 2 (Patients): * Patients not initiating Kaposi Sarcoma treatment * Very ill patients requiring hospitalization Inclusion Criteria - Aim 3 (Patients): * Adults age ≥18 years old * Histopathology-confirmed Kaposi Sarcoma * Capable of informed consent * Initiating treatment for Kaposi Sarcoma Exclusion Criteria - Aim 3 (Patients): * Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2 * Prior or ongoing Kaposi Sarcoma treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Kaposi sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Infectious Diseases Institute, Makerere University
RECRUITINGKampala, Uganda
-
Kenya Medical Research Institute
NOT_YET_RECRUITINGKisumu, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets rare, aggressive cancer
- Kaposi's sarcoma drug trial halted early – what we know
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- New drug shows promise in blocking kaposi sarcoma growth
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin